Fda clears mindmed ind for mm-120 in treatment of generalized anxiety disorder

New york , jan. 25, 2022 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (de: mmq) (the "company"), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced today that the u.s. food and drug administration (fda) has cleared mindmed's investigational new drug (ind) application, allowing the company's phase 2b dose-optimization trial of mm-120 for the treatment of generalized anxiety disorder (gad) to proceed. the previously announced clinical hold on the ind was lifted following mindmed's rapid responses for additional information related to the participant monitoring protocol in the upcoming study.
MNMD Ratings Summary
MNMD Quant Ranking